US 11618731
Prodrugs of kallikrein inhibitors
granted A61PA61P29/00
Quick answer
US patent 11618731 (Prodrugs of kallikrein inhibitors) held by BioCryst Pharmaceuticals, Inc. expires Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BioCryst Pharmaceuticals, Inc.
- Grant date
- Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 13
- CPC classes
- A61P, A61P29/00